Note 4 - Stock-based Compensation	6 Months Ended
Sep. 30, 2021
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	Note 4: Stock-Based Compensation The Company records compensation expense associated with restricted stock in accordance with ASC Topic 718 (“Share Based Payment”) (ASU 2016-09). The compensation expense related to all of the Company’s stock-based compensation arrangements is recorded as a component of general and administrative expenses. The Company had 861,275 restricted common shares issued under the 2016 Employee Equity Compensation Restricted Stock Plan (“2016 Employee Plan”) and 203,880 restricted common shares issued under the 2015 Outside Director Equity Compensation Restricted Stock Plan (“2015 Director Plan”) at September 30, 2021, all shares of which were issued subject to a restriction or forfeiture period that lapses ratably on the first, second, and third anniversaries of the date of grant, and the fair value of which is being amortized over the three-year restriction period. In July 2021, the Company issued 41,745 restricted shares to certain employees of the Company under the 2016 Employee Plan, with a fair value of $31.39 per share. In August 2021, the Company issued 90,000 restricted shares and 510,000 performance restricted shares to the Company’s CEO, in accordance with the CEO’s employment agreement, under the 2016 Employee Plan. The fair value of the 90,000 restricted shares issuance was valued at $28.70 per share. The value of the 510,000 performance restricted shares issuance was valued by a third party valuation firm, and these shares were valued at $9.7 million, or $19.06 per share. The valuation firm utilized a Monte Carlo model to value the 510,000 performance restricted shares and looked at several other factors such as historical stock price volatility. In July 2021, the Company issued 37,500 restricted shares to directors of the Company under the 2015 Director Plan, with a fair value of $31.39 per share. In September 2021, the Company issued 1,350 restricted shares to a certain employee of the Company under the 2016 Employee Plan, with a fair value of $26.87 per share. For the quarters ended September 30, 2021 and 2020, the Company recognized $882,000 and $772,000, respectively, of compensation expense related to the 2016 Employee and 2015 Director Plans. For the six months ended September 30, 2021 and 2020, the Company recognized $1.6 million and $1.5 million, respectively, of compensation expense related to the 2016 Employee and 2015 Director Plans. At September 30, 2021 and 2020, there was $15.8 million and $4.4 million of unrecognized compensation cost related to the non-vested restricted stock awards, respectively, which is expected to be recognized over the next three years. All stock-based compensation expense is recognized as a payroll-related expense and it is included within the general and administrative expenses line item within the income statement, and the offset is included in the additional paid-in capital line item of the balance sheet. At September 30, 2021 and 2020 there were approximately 734,669 and 177,876 non-vested restricted shares, respectively.

Note 4 - Stock-based Compensation

6 Months Ended

Sep. 30, 2021

Share-based Payment Arrangement [Text Block]

Note 4: Stock-Based Compensation

The Company records compensation expense associated with restricted stock in accordance with ASC Topic 718 (“Share Based Payment”) (ASU 2016-09). The compensation expense related to all of the Company’s stock-based compensation arrangements is recorded as a component of general and administrative expenses. The Company had 861,275 restricted common shares issued under the 2016 Employee Equity Compensation Restricted Stock Plan (“2016 Employee Plan”) and 203,880 restricted common shares issued under the 2015 Outside Director Equity Compensation Restricted Stock Plan (“2015 Director Plan”) at September 30, 2021, all shares of which were issued subject to a restriction or forfeiture period that lapses ratably on the first, second, and third anniversaries of the date of grant, and the fair value of which is being amortized over the three-year restriction period.

In July 2021, the Company issued 41,745 restricted shares to certain employees of the Company under the 2016 Employee Plan, with a fair value of $31.39 per share. In August 2021, the Company issued 90,000 restricted shares and 510,000 performance restricted shares to the Company’s CEO, in accordance with the CEO’s employment agreement, under the 2016 Employee Plan. The fair value of the 90,000 restricted shares issuance was valued at $28.70 per share. The value of the 510,000 performance restricted shares issuance was valued by a third party valuation firm, and these shares were valued at $9.7 million, or $19.06 per share. The valuation firm utilized a Monte Carlo model to value the 510,000 performance restricted shares and looked at several other factors such as historical stock price volatility. In July 2021, the Company issued 37,500 restricted shares to directors of the Company under the 2015 Director Plan, with a fair value of $31.39 per share. In September 2021, the Company issued 1,350 restricted shares to a certain employee of the Company under the 2016 Employee Plan, with a fair value of $26.87 per share.

For the quarters ended September 30, 2021 and 2020, the Company recognized $882,000 and $772,000, respectively, of compensation expense related to the 2016 Employee and 2015 Director Plans. For the six months ended September 30, 2021 and 2020, the Company recognized $1.6 million and $1.5 million, respectively, of compensation expense related to the 2016 Employee and 2015 Director Plans. At September 30, 2021 and 2020, there was $15.8 million and $4.4 million of unrecognized compensation cost related to the non-vested restricted stock awards, respectively, which is expected to be recognized over the next three years. All stock-based compensation expense is recognized as a payroll-related expense and it is included within the general and administrative expenses line item within the income statement, and the offset is included in the additional paid-in capital line item of the balance sheet. At September 30, 2021 and 2020 there were approximately 734,669 and 177,876 non-vested restricted shares, respectively.